Company signals · Biotech & Pharma
Biogen Inc.
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: MitchelLake's Talent Market Index sits at 95.4 (Cool), down 5.3 on the prior month; EMEA hiring signal is running rising (+5pts).
Biogen Inc.: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies.
Signals at Biogen Inc.
Biogen Inc. signals in the last 90 days
1 public signal observed since 22 August 2026, by type.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · EMEA
AviadoBio →AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.
Product Launch · EMEA
Boehringer Ingelheim →Boehringer Ingelheim announced Phase III trial success for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, achieving 13.1% average weight loss in obesity and type 2 diabetes patients. Results published in NEJM and presented at EASD conference.
Product Launch · EMEA
Teva Pharmaceuticals →Teva Pharmaceuticals reported successful topline results from a gluten challenge study showing that a single injection of an experimental antibody significantly reduced intestinal damage in celiac disease patients who consumed gluten daily.
Product Launch · EMEA
Biogen →Biogen and Eisai gained FDA approval for LEQEMBI IQLIK, an at-home subcutaneous autoinjector for Alzheimer's treatment, plus Phase 2 data showing tau reduction with investigational therapy diranersen. Positions Biogen as leader in amyloid- and tau-targeting approaches.
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Product Launch · EMEA
Amgen →European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Where Biogen Inc.'s market lands in our work
- Product Technology Executive Search →
A launch is the output of a product and engineering leadership layer built before it.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
- Data period
- 2 Oct 2026 – 2 Oct 2026 · 1 signals for this company
- Methodology
- How this is computed
- Publisher
- MitchelLake
Last updated
